The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Local recurrence after surgery for early stage lung cancer: An 11‐year experience with 975 patients
Open accessAbstract
BACKGROUND: The objective of the current study was to evaluate the actuarial risk of local failure (LF) after surgery for stage I to II nonsmall cell lung cancer (NSCLC) and assess surgical and pathologic factors affecting this risk. METHODS: The records, including pertinent radiologic studies, of all patients who underwent surgery for T1 to T2, N0 to N1 NSCLC at Duke University between 1995 and 2005 were reviewed. Risks of disease recurrence were estimated using the Kaplan‐Meier method. A multivariate Cox regression analysis assessed factors associated with LF in the entire cohort and a subgroup undergoing optimal surgery for stage IB to II disease. RESULTS: For all 975 consecutive patients, the 5‐year actuarial risk of local and/or distant disease recurrence was 36%. First sites of failure were local only (25%), local and distant (29%), and distant only (46%). The 5‐year actuarial risk of LF was 23%. On multivariate analysis, squamous/large cell histology (hazards ratio [HR], 1.98), stage > IA (HR, 2.02), and sublobar resections (HR, 1.99) were found to be independently associated with a higher risk of LF. For the subset of patients (n = 445) undergoing at least a lobectomy with negative surgical margins and currently considered for adjuvant chemotherapy (stage IB‐II disease), the 5‐year actuarial risk of LF was 27%. Within this subgroup, squamous/large cell histology (HR, 2.5) and lymphovascular space invasion (HR, 1.74) were associated with a higher risk of LF. The 5‐year rate of LF was 13%, 32%, and 47%, respectively, with 0, 1, or 2 risk factors. CONCLUSIONS: Greater than half of disease recurrences after surgery for early stage NSCLC involved local sites. Pathologic factors may help to distinguish those patients at highest risk. Cancer 2009. © 2009 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
A Genomic Strategy to Refine Prognosis in Early-Stage Non–Small-Cell Lung Cancer
Potti, A., Mukherjee, S., Petersen, R., Dressman, H. K., Bild, A., Koontz, J., Kratzke, R., Watson, M. A., Kelley, M., Ginsburg, G. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060467 · Cited by 576
RetractedPractical Statistics for Medical Research.
Walter, S. D., & Altman, D. G. (1992) · Biometrics · doi:10.2307/2532320 · Cited by 11,668
Practical Statistics for Medical Research
Altman, D. G. (1990) · doi:10.1201/9780429258589 · Cited by 10,668
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer
Ginsberg, R. J., & Rubinstein, L. V. (1995) · The Annals of Thoracic Surgery · doi:10.1016/0003-4975(95)00537-u · Cited by 3,006
Non-small Cell Lung Cancer Collaborative Group (1995) · BMJ · doi:10.1136/bmj.311.7010.899 · Cited by 2,850
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Pignon, J.-P., Tribodet, H., Scagliotti, G. V., Douillard, J.-Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9030 · Cited by 2,642
CONSORT statement: extension to cluster randomised trials
Campbell, M. K., Elbourne, D. R., & Altman, D. G. (2004) · BMJ · doi:10.1136/bmj.328.7441.702 · Cited by 2,557
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa031644 · Cited by 2,335
Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer
Winton, T., Livingston, R., Johnson, D., Rigas, J., Johnston, M., Butts, C., Cormier, Y., Goss, G., Inculet, R., Vallieres, E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043623 · Cited by 1,810
Douillard, J.-Y., Rosell, R., De Lena, M., Carpagnano, F., Ramlau, R., Gonzáles-Larriba, J. L., Grodzki, T., Pereira, J. R., Le Groumellec, A., Lorusso, V., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70804-x · Cited by 1,573
Incidence of local recurrence and second primary tumors in resected stage I lung cancer
Martini, N., Bains, M. S., Burt, M. E., Zakowski, M. F., McCormack, P., Rusch, V. W., & Ginsberg, R. J. (1995) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(95)70427-2 · Cited by 973
A Five-Gene Signature and Clinical Outcome in Non–Small-Cell Lung Cancer
Chen, H.-Y., Yu, S.-L., Chen, C.-H., Chang, G.-C., Chen, C.-Y., Yuan, A., Cheng, C.-L., Wang, C.-H., Terng, H.-J., Kao, S.-F., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060096 · Cited by 935
A Randomized Trial of Adjuvant Chemotherapy with Uracil–Tegafur for Adenocarcinoma of the Lung
Kato, H., Ichinose, Y., Ohta, M., Hata, E., Tsubota, N., Tada, H., Watanabe, Y., Wada, H., Tsuboi, M., Hamajima, N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032792 · Cited by 818
Modelling Survival Data in Medical Research (2nd ed.) (Book)
Cowles, M. K. (2004) · Quarterly Publications of the American Statistical Association · Cited by 369
Harpole, D. H., Herndon, J. E., Young, W. G., Wolfe, W. G., & Sabiston, D. C. (1995) · Cancer · doi:10.1002/1097-0142(19950901)76:5<787::aid-cncr2820760512>3.0.co;2-q · Cited by 322
Sites of recurrence in resected stage I non-small-cell lung cancer: a guide for future studies.
Feld, R., Rubinstein, L. V., & Weisenberger, T. H. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.12.1352 · Cited by 321
Warren, W. H., & Faber, L. P. (1994) · PubMed · Cited by 284
Segmentectomy versus lobectomy in patients with stage I pulmonary carcinoma
Warren, W. H., & Faber, L. P. (1994) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(12)70385-9 · Cited by 255
Melnick, E. L. (2025) · International Encyclopedia of Statistical Science · doi:10.1007/978-3-662-69359-9_374 · Cited by 228
Improved methodology for analyzing local and distant recurrence.
Gelman, R., Gelber, R., Henderson, I. C., Coleman, C. N., & Harris, J. R. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.3.548 · Cited by 224
Cited by
Treatment of Stage I and II Non-small Cell Lung Cancer
Howington, J. A., Blum, M. G., Chang, A. C., Balekian, A. A., & Murthy, S. C. (2013) · Chest · doi:10.1378/chest.12-2359 · Cited by 1,440
Wolinsky, J. B., Colson, Y. L., & Grinstaff, M. W. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.11.031 · Cited by 845
Early stage NSCLC — challenges to implementing ctDNA-based screening and MRD detection
Abbosh, C., Birkbak, N. J., & Swanton, C. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0058-3 · Cited by 450
Der, S. D., Sykes, J., Pintilie, M., Zhu, C.-Q., Strumpf, D., Liu, N., Jurisica, I., Shepherd, F. A., & Tsao, M.-S. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000042 · Cited by 372
Local Cancer Recurrence: The Realities, Challenges, and Opportunities for New Therapies
Mahvi, D. A., Liu, R., Grinstaff, M. W., Colson, Y. L., & Raut, C. P. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21498 · Cited by 338
Metadata
- Authors
- Kelsey, C. R., Marks, L. B., Hollis, D., Hubbs, J. L., Ready, N. E., D'Amico, T. A., & Boyd, J. A.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2009-11-03
- Volume
- 115
- Issue
- 22
- Pages
- 5218-5227
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1975727847
- Cited by
- 295
- References
- 23
- FWCI
- 8.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.